Looking for real undervalued companies.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Synergy finds some good companies to sell the shells to look at FTRS. I love the track record of Synergy and EMDF is just waiting to run
The word will continue to spread this could make a real move if enough people catch wind to it.
Yes the wealthy Gary Kompothecras just took over. His company Continuation Capitol http://continuecap.com is involved with SFOR
He owns Hotels, Clinics etc he is the executive producer of the MTV series Siesta Key
Nice chances here with this 42M OS
The wealthy Gary Kompothecras just took over $EMDF from @synergymgtgroup
— Rise2ShineLife (@Rise2ShineLife) March 23, 2021
His company Continuation Capitol https://t.co/hB4x4RAYzo is involved with $SFOR @GeorgeASharp
He owns Hotels, Clinics etc he is the executive producer of the #MTV series #SiestaKey
42M OS on this one👀👇 pic.twitter.com/ev1vwN186B
What? The article is about the skate board Ocean spray tik tok guy who went viral last year. I guess he sold a NFT for $500k. Why would the company be mentioned in that article for any reason?
They should put that packet in a PR so the general public can see it.
Pre run here $IMTL is just getting started
Going to get real next week I'm glad I held all my IMTL shares!
Every company sells stock or uses it for acquisitions at some point or another everyone knows that.
New tweet out by the CEO boom!
$IMTL new tweet from the CEO more on #blockchain #Crypto #Media and #images next week boom! #pinkcurrent coming stay tuned! https://t.co/vQE9O7n5EB
— Rise2ShineLife (@Rise2ShineLife) March 19, 2021
The bid whacker can sell the rest of their shares at .30 or less I will get on the bid next week
They have no idea on how OTC thinks with those dull PR's
Longs wont even hit the ask to support the stock they do nothing but sit around and wait on the company, no tweets won't even retweet a tweet. The company needs to put out some news and we need some more active shareholders this is OTC it's important to keep eyes on a stock that doesn't have a decent size active shareholder following.
Back to .30s on the bid smh I knew this was coming the minute I stopped tweeting
Waiting on a update from Gary to see what the direction he is taking this shell interesting that Vincent Payne is listed as Secretary and Treasurer on the NVSOS because his https://www.linkedin.com/in/vincent-payne-1308475/ says he is the CFO of:
Healthcare Management Enterprises, Inc.
Jan 2008 - Present13 years 3 months
Operator of 50 clinics in Florida, Kentucy and Minnesota. Practice is centered around physical therapy, pain management, surgery, MRI and diagnostic services for accident victims.
Interesting both Gary and Vincent are involved with Clinics
$EMDF could be a $MiTi 2.0 if Gary Kompothecras brings in his 25 clinic business
— Rise2ShineLife (@Rise2ShineLife) March 18, 2021
NVSOS address he used matches his business https://t.co/KfA3VWCfM4$Miti .02 to .49 189M OS $EMDF .088 right now with a 42M OS
Just need confirmation on what he is doing with the shell$IMTL pic.twitter.com/FYU5RMYs5r
Nice that means filings being reviewed and you know what happens once OTC is satisfied with adjustments.
The fun will start when you least expect it. Gary is a big money guy so this is going to be interesting to see what the plan is here.
I'm not talking about what other people said whenever concerning whomever. I'm talking about what's going on here at the moment and your .005 seemed a lot off considering the circumstances I laid out.
Do you know how many shares sold above .01? Everyone knows pink current is coming and a PR firm was hired so it's not rocket science to see news in some form is coming.
It was a mistake: We are working on filing an amendment to our January 31st Quarterly Report. The changes will be to Page 4 of the report under "Security Information." The dates listed should read January 31st NOT March 16th.
We are working on filing an amendment to our January 31st Quarterly Report. The changes will be to Page 4 of the report under "Security Information." The dates listed should read January 31st NOT March 16th. $FTRS
— Futuris Company (@FuturisCompany) March 17, 2021
Churn the flippers out as we climb back up stronger. Did they realize how many shares was sold above .01 while at the same time dilution looks to have ended. Now throw in 2 catalyst any day now and you got a good probability of this going higher.
I'm done tweeting this stock trying to keep new eyes on it. When something new happens and worth tweeting I will.
News hasn't even hit yet does anyone hold to see what the company has planned? Certainly some will.
Locked and loaded for news.
We should see filings soon Synergy said they will start working with companies that want to move fast.
Added some here last week, I'm looking forward to a real move on this one.
Nice update because we need some solid news the stock deserves more attention than it's been getting.
They need to put out better PR's that spark interest these boring releases won't get it.
$IMTL is in beast mode!
Any and everywhere I'm concerned until it's confirmed no.
Developer Gary Kompothecras, the founder of the medical referral service 1-800 Ask Gary and a prominent Republican donor, is proposing to build a 120-room hotel and five-story parking garage on Old Stickney Point Road, just west of the drawbridge on Stickney Point Road.
https://www.heraldtribune.com/story/news/local/sarasota/2020/12/05/ask-gary-siesta-key-hotel-proposal-gets-earful-first-workshop/3784205001/
Yes the crowd hasn't come yet and the potential here is crazy we could land the 25 location clinic
Is that the company coming can you post some links. They have 25 locations
$EMDF BOOM! @synergymgtgroup update just out: "Wrapping up EMDF (XL Rent, Inc.) and have done elections which will be posted to NV SOS today."$AVSR $STHC $AGSO $FTRS $TSNP $CTYX $STHC #merger #StockMarket #StocksToWatch pic.twitter.com/OmoXAfpHlh
— Rise2ShineLife (@Rise2ShineLife) March 12, 2021
She wants to break .01 you should let her go
They will never give out info like that I called them several times concerning different tickers once you mention a company name they won't comment
News out Connectyx Reports Fiscal Year 2020 Financial Results
March 09, 2021 10:24 ET | Source: Connectyx Technologies Holdings Group, Inc
Biotechnology Company Issues Highlights and Subsequent Events
Boca Raton, Fla, March 09, 2021 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel treatments for rare diseases, announced that it has filed financial results for the fiscal year ended December 31, 2020. As reported in late 2020, Connectyx registered with the State of Florida to become Curative Biotechnology, Inc. and has applied for the name change and a trading symbol change to “CURB” with the Financial Industry Regulatory Authority, Inc. (FINRA).
The annual report can be accessed at OTC Markets Group:
https://www.otcmarkets.com/stock/CTYX/disclosure
Assets and Balance Sheet reflects substantial improvement over Fiscal Year 2019 including the addition of:
CURB906 - Company entered into an Exclusive Evaluation and Commercialization Option License Agreement with the National Cancer Institute (NCI), for the use of a First in Class Antibody Drug Conjugate for Targeting CD56 Positive Brain Tumors.
IMT504 - Company entered into a worldwide license agreement with MidAtlantic BioTheraputics, Inc. (MABT), to license the development of a novel immunostimulatory drug; IMT504 as an immunotherapy for late-stage symptomatic rabies.
3. Preliminary bridge financing through a combination of straight debt instruments ($565,000) and the exercise of warrants ($525,000) in exchange for one year restricted shares for a total of $1.09 Million.
Subsequent to the Fiscal year-end:
Company engaged Public Company Accounting Oversight Board (PCAOB) auditor, Daszkal Bolton LLP, to serve as the auditor for the Company to become SEC reporting.
Company also launched an updated website for Curative Biotech: https://curativebiotech.com/
Company announced the addition of three (3) biotechnology veterans with extensive experience in clinical development, regulatory affairs, manufacturing, business development and patent portfolio direction to senior management. https://www.prnewswire.com/news-releases/connectyx-announces-key-biotech-industry-veterans-to-management-team-301226516.html
In February 2021, the Company entered into an Exclusive Patent License Agreement to practice inventions with the National Eye Institute (NEI) of the National Institutes of Health (NIH), including the repurposed use of Metformin to treat Retinal Degeneration (RD).
Chairman Michaels noted, “We have made tremendous progress in the remaking of this company in the past twelve months. We have acquired three important therapeutic development programs, have brought in an outstanding experienced life science industry management team, and we have raised $1.09 million in a preliminary financing. I believe 2021 will bring more growth to the company as our programs begin to move towards the clinic and as we continue to demonstrate that we can execute on our core business model of acquiring assets under economically sustainable terms and adding inflection point value.
About Connectyx Technologies Holdings Group, Inc. http://curativebiotech/
Connectyx is a development-stage biomedical company focusing on novel treatments for rare diseases. In November, the Company announced it is changing its name to Curative Biotechnology, Inc. and has applied for the name change and a trading symbol (CURB) with the Financial Industry Regulatory Authority, Inc., which should take effect in the first quarter of 2021. Connectyx is focused on therapies with potentially accelerated development paths as a result of either the disease, the nature of the therapeutic itself, or the stage of clinical development. At the heart of the Company is a product development engine that rests on our unique S.O.A.R. filter (Science, Opportunity, Acceleration, Rare Disease.) At Connectyx, we envision a world where all patients have a therapeutic option.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. CTYX is not yet generating revenues. Although forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subjected to known, unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements, including but not limited our ability to generate sufficient market acceptance for our products and services, our ability to generate sufficient operating cash flow, and general economic conditions. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with OTC Markets from time to time which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Contact:
Connectyx Technologies Holdings Group, Inc.
ir@curativebiotech.com
Paul Michaels
561-418-7725
https://www.globenewswire.com/news-release/2021/03/09/2189768/0/en/Connectyx-Reports-Fiscal-Year-2020-Financial-Results.html
$CTYX $CURB highlights news out: https://t.co/qWQRksfNu6$EYES $MiTi #StocksToWatch #stocks #RareDisease #bigpharma
— Rise2ShineLife (@Rise2ShineLife) March 9, 2021